Lutathera

Adult Dosing .

Dosage forms:  INJ

Restricted Distribution in US

[1-888-669-6682 or www.lutathera.com for more info]

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for XRT safety procedures, uses, premeds, concomitant meds, and dosing incl. toxicity-related dose adjustments

gastroenteropancreatic neuroendocrine tumor

[7.4 GBq IV q8wk x4 doses]

Info: for somatostatin receptor-positive dz; d/c long-acting somatostatin analogs at least 4wk before each dose; d/c short-acting somatostatin analogs at least 24h before each dose; give w/ long-acting octreotide 4-24h after each dose, cont. long-acting octreotide after tx for up to 18mo total; give w/ amino acid solution 30min before, during, and for at least 3h after each dose

prostate CA, metastatic castration-resistant (off-label)

[7.4 GBq IV q6wk for up to 6 doses]

Info: for pts w/ progressive prostate-specific membrane antigen (PSMA)-positive dz

renal dosing

[see below]

CrCl >30: no adjustment; CrCl <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

mild-moderate impairment: no adjustment; severe impairment: not defined

Peds Dosing .

Dosage forms:  INJ

Restricted Distribution in US

[1-888-669-6682 or www.lutathera.com for more info]

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for XRT safety procedures, uses, premeds, concomitant meds, and dosing incl. toxicity-related dose adjustments

gastroenteropancreatic neuroendocrine tumor

[12 yo and older]

Dose: 7.4 GBq IV q8wk x4 doses; Info: for somatostatin receptor-positive dz; give w/ amino acid solution 30min before, during, and for at least 3h after each dose

renal dosing

[not defined]

renal impairment: consider adult renal dosing for guidance

HD/PD: not defined

hepatic dosing

[see below]

mild-moderate impairment: no adjustment; severe impairment: not defined